Investing

Top Analyst Upgrades and Downgrades: AbbVie, Agilent, Albermarle, Apple, Boeing, Cheniere, First Solar, HCA, LabCorp, Lumber Liquidators, Teva and More

Jon C. Ogg

Danaher Corp. (NYSE: DHR) was started with a Buy rating and assigned a $114 target price at Needham.

DaVita Inc. (NYSE: DVA) was started with a Buy rating and assigned a $60 target price (versus a $51.73 close) at Deutsche Bank.

First Solar Inc. (NASDAQ: FSLR) was raised to Buy from Neutral at Goldman Sachs, and the firm raised its target price to $57 from $48. The stock closed at $42.56 on Wednesday but was indicated up over 3% at $44.00 on Thursday. Its consensus target was $64.10, and its 52-week trading range is $36.51 to $81.72.

Genomic Health Inc. (NASDAQ: GHDX) was started with a Strong Buy rating and assigned an $86 price target (versus a $62.22 close) at Needham.

HCA Healthcare Inc. (NYSE: HCA) was started with a Buy rating and assigned a $140 price target (versus a $121.76 close) at Deutsche Bank.

Integra LifeSciences Holdings Corp. (NASDAQ: IART) was started as Buy and assigned a $56 target price (versus a $43.74 close) at SunTrust Robinson Humphrey.

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) was raised to Neutral from Underperform at Merrill Lynch.

Laboratory Corp. of America Holdings (NYSE: LH) was downgraded to Underperform from Neutral at Merrill Lynch.

Lumber Liquidators Holdings Inc. (NYSE: LL) was downgraded to Hold from Buy and the price target was slashed to $10 from $24 at (versus a $9.97 close) at Loop Capital.

Myriad Genetics Inc. (NASDAQ: MYGN) was started with a Strong Buy rating and assigned a $36 target price at Needham.

Quest Diagnostics Inc. (NYSE: DGX) was downgraded to Underperform from Neutral at Merrill Lynch.

Robert Half International Inc. (NYSE: RHI) was downgraded to Neutral from Buy at Merrill Lynch.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) was raised to Buy from Underperform at Merrill Lynch. Shares were indicated up 1.7% at $16.13 on Thursday, after closing up 2.8% at $15.85 on Wednesday.

Waters Corp. (NYSE: WAT) was raised to Neutral from Underperform at Merrill Lynch.

Goldman Sachs issued a late 2018 note signaling that 2019 might not be as bad as the markets have worried about.

Apple has proved our hunch that analyst estimates need to be brought down almost unilaterally at the start of 2019. The reason we felt that way, the consensus Dow price targets would have indicated a Dow 28,000 for 2019.

Also see the consensus analyst outlook for the top biotech leaders of 2019, at least before the Celgene acquisition news.

Wednesday’s top analyst calls included Aflac, Akamai, BioMarin, Caesars Entertainment, CBS, Crocs, GW Pharma, Medtronic, Netflix, Sirius XM and many more.